TIDM0Y71

RNS Number : 5428N

Malin Corporation PLC

21 May 2020

Malin Corporation plc

Poseida Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer

Dublin-Ireland, 21 May 2020 : Malin Corporation plc. (Euronext Growth Dublin:MLC) ("Malin"), a company investing in highly innovative life sciences companies, is pleased to note that Poseida Therapeutics, Inc. ("Poseida"), one of Malin's Priority Assets, has announced the first patient has been dosed in its Phase 1 clinical trial evaluating P-PSMA-101, its autologous CAR-T therapeutic candidate, in metastatic castration-resistant prostate cancer.

P-PSMA-101 is designed to target prostate-specific membrane antigen, which is expressed on metastatic castration-resistant prostate cancer cells and was developed using Poseida's proprietary piggyBac DNA Modification System. The study represents a promising advancement in evolving cell therapies to treat solid tumours. As part of its research, Poseida's Phase 1 open label, multi-centre, dose-escalating trial will include cohorts receiving single and multiple doses of P-PSMA-101, with the goal of determining the best dose with fewest side effects.

A copy of Poseida's press release is available to view here: https://poseida.com/poseida-therapeutics-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-p-psma-101-autologous-car-t-for-metastatic-castration-resistant-prostate-cancer/

Poseida is a clinical-stage biopharmaceutical company dedicated to utilising proprietary non-viral gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.

ENDS

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com

For further information please contact:

Malin

Jessica Bergin, Investor Relations & External Reporting

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Davy Corporate Finance (Euronext Growth Adviser & Joint Broker)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

Liberum (Joint Broker)

Bidhi Bhoma / Euan Brown

Tel: +44 (0) 20 3100 2000

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh

Tel: +44 (0)20 3709 5700

malin@consilium-comms.com

Powerscourt (Irish media enquiries)

Eavan Gannon

Tel: +353 87 236 5973

malin@powerscourt-group.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RESURSNRRAUVUAR

(END) Dow Jones Newswires

May 21, 2020 02:00 ET (06:00 GMT)

Malin (LSE:0Y71)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Malin Charts.
Malin (LSE:0Y71)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Malin Charts.